Latest Share Chat

REMOVE ADS

Faron Pharmaceuticals Share News (FARN)

Faron Pharmaceuticals Information

Share Price Information for Faron Pharmaceuticals (FARN)

Share Price is delayed by 15 minutes

Get Live Data

46.00 -1.40 (-2.95%)

Bid:

45.00

Ask:

47.00

Spread: 2.00 (4.444%)

Market Cap: £91.78m

Last checked at -

Intraday Faron Pharmaceuticals Share Chart

REMOVE ADS

Faron Pharmaceuticals News

TRADING UPDATES: Tungsten West 'largest Western tungsten producer'

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Faron Pharmaceuticals sees patient remission in immunotherapy trials

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it was encouraged by promising early data from trials for its investigative precision immun...

TRADING UPDATES: Renalytix hails trial results; Kingswood buys JFP

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Joules nomad resigns; Pharma C loss narrows

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

TRADING UPDATES: 4Global wins deal; James Cropper profit warning

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Faron Pharmaceuticals shares down as raises EUR8.4 million in placing

(Alliance News) - Faron Pharmaceuticals Ltd shares declined on Friday, after it said it has raised EUR8.4 million from a share placing.

TRADING UPDATES: Bidstack names new COO; Fintel expands deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

REPEAT: Faron Pharma half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widened, as the company reported higher research and administrative expe...